Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations

References

• Dreyling M, Geisler C, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii83–iii92.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Jerkeman M, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2017;28(Suppl 4):iv62–iv71.
   Web of Science ®Google Scholar
• Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117:26–38.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• Avivi I, Goy A. Refining the mantle cell lymphoma paradigm: impact of novel therapies on current practice. Clin Cancer Res. 2015;21:3853–3861.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185–197.
   PubMed Web of Science ®Google Scholar
• Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70:1408–1418.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27:1209–1213.
   PubMed Web of Science ®Google Scholar
• Abrahamsson A, Albertsson-Lindblad A, Brown PN, et al. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood. 2014;124:1288–1295.
   PubMed Web of Science ®Google Scholar
• Chandran R, Gardiner SK, Simon M, et al. Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007. Leuk Lymphoma. 2012;53:1488–1493.
   PubMed Web of Science ®Google Scholar
• Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:511–518.
   PubMed Web of Science ®Google Scholar
• Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN^® Guidelines) for Non-Hodgkin's Lymphoma V.3.2017. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed September 5, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
   Google Scholar
• McKay P, Leach M, Jackson R, British Committee for Standards in H, et al. Guidelines for the investigation and management of mantle cell lymphoma. Br J Haematol. 2012;159:405–426.
   PubMed Web of Science ®Google Scholar
• Goy A, Kahl B. Mantle cell lymphoma: the promise of new treatment options. Crit Rev Oncol Hematol. 2011;80:69–86.
   PubMed Web of Science ®Google Scholar
• Trneny M, Klener P, Belada D, et al. The outcome of mantle cell lymphoma patients after treatment failure and prognostic value of secondary mantle cell international prognostic index (sec MIPI). Blood. 2014;124:Abstract 4425.
   Web of Science ®Google Scholar
• Ohmachi K, Ando K, Ogura M, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010;101:2059–2064.
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4473–4479.
   PubMed Web of Science ®Google Scholar
• Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17:57–66.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Goy A, Lamonica D, et al. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Ann Hematol. 2015;94:2025–2032.
   PubMed Web of Science ®Google Scholar
• Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31:1442–1449.
   PubMed Web of Science ®Google Scholar
• Garbo LE, Flynn PJ, MacRae MA, et al. Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma. Invest New Drugs. 2009;27:476–481.
   PubMed Web of Science ®Google Scholar
• Gironella M, Lopez A, Merchan B, et al. Rituximab plus gemcitabine and oxaliplatin as salvage therapy in patients with relapsed/refractory mantle cell lymphoma. Blood. 2012;120:Abstract 1627.
   Web of Science ®Google Scholar
• Obrador-Hevia A, Serra-Sitjar M, Rodriguez J, et al. Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma. Br J Haematol. 2016;174:899–910.
   PubMed Web of Science ®Google Scholar
• Moita F, Santos J, da Silva MG. Fludarabine-based combination chemotherapy in relapsed mantle cell lymphoma – the experience of a single center. Haematologica. 2012;97:Abstract 0256.
   Google Scholar
• Coleman M, Martin P, Ruan J, et al. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma. 2008;49:447–450.
   PubMed Web of Science ®Google Scholar
• Wang M, Fayad L, Cabanillas F, et al. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer. 2008;113:2734–2741.
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius JF, Trelle S, et al. Immunochemo-therapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99:706–714.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383–3389.
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944–2952.
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Chang J, et al. First-line treatment of iNHL of MCL patients with BR or R-CHOP/R-CVP: results of the BRIGHT 5-year follow-up study. Hematol Oncol. 2017;101:140–141. Abstract 131.
   Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–1210.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Maschmeyer G, Ganser A, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study. J Clin Oncol (ASCO Annual Meeting Abstracts) 2017;35:abstract 7501.
   Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516.
   PubMed Web of Science ®Google Scholar
• Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739–745.
   PubMed Web of Science ®Google Scholar
• Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688–3695.
   PubMed Web of Science ®Google Scholar
• Goy A, Kalayoglu Besisik S, Drach J, et al. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial. Br J Haematol. 2015;170:496–503.
   PubMed Web of Science ®Google Scholar
• Trneny M, Lamy T, Walewski J, et al. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016;17:319–331.
   PubMed Web of Science ®Google Scholar
• Stefoni V, Pellegrini C, Gandolfi L, et al. Lenalidomide in pretreated mantle cell lymphoma patients: an Italian observational multicenter retrospective study in daily clinical practice, the Lenamant study. Blood. 2015;126: Abstract 3946. (ASH proceedings)
   Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22:1622–1627.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Vose JM, Czuczman MS, et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol. 2013;24:2892–2897.
   PubMed Web of Science ®Google Scholar
• Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol. 2012;159:154–163.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145:344–349.
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822–3829.
   PubMed Web of Science ®Google Scholar
• Hoy SM, McKeage K. Temsirolimus: In relapsed and/or refractory mantle cell lymphoma. Drugs. 2010;70:1819–1829.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Inwards DJ, Rowland KM, Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008;113:508–514.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387:770–778.
   PubMed Web of Science ®Google Scholar
• Rule S, Jurczak W, Jerkeman M, et al. Ibrutinib vs temsirolimus: three-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Hematol Oncol. 2017;101:143–144. Abstract 134.
   Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–4874.
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20:520–525.
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Moskowitz C, Portlock C, et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. Br J Haematol. 2009;145:34–39.
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Portlock C, Moskowitz C, et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res. 2010;16:719–726.
   PubMed Web of Science ®Google Scholar
• Gerecitano J, Portlock C, Moskowitz C, et al. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol. 2009;146:652–655.
   PubMed Web of Science ®Google Scholar
• Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2912–2919.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014;123:3398–3405.
   PubMed Web of Science ®Google Scholar
• TORISEL (temsirolimus) prescribing information. Kent, United Kingdom: Pfizer Limited; 2017.
   Google Scholar
• IMBRUVICA (ibrutinib) prescribing information. Belgium: Janssen-Cilag International NV; 2017.
   Google Scholar
• REVLIMID (lenalidomide) prescribing information. United Kingdom: Celgene Europe Limited; 2017.
   Google Scholar
• IMBRUVICA (ibrutinib) prescribing information. Sunnyvale (CA): Pharmacyclics, Inc.; 2017.
   Google Scholar
• REVLIMID (lenalidomide) prescribing information. Summit (NJ): Celgene Corporation; 2017.
   Google Scholar
• VELCADE (bortezomib) prescribing information. Cambridge (MA): Millennium Pharmaceuticals, Inc.; 2017.
   Google Scholar
• Wang M, Goy A, Martin P, et al. Efficacy and safety of single-agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy. Blood (ASH Proceedings). 2014;124:Abstract 4471.
   Google Scholar
• Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127:1559–1563.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26:1175–1179.
   PubMed Web of Science ®Google Scholar
• Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012;13:716–723.
   PubMed Web of Science ®Google Scholar
• Trneny M, Lamy T, Walewski J, et al. Impact of prior treatment on PFS for relapsed/refractory mantle cell lymphoma patients randomized to lenalidomide vs investigator's choice: a subgroup analysis of the phase II MCL-002 (SPRINT) study. Haematologica (EHA Meeting Proceedings). 2015;100:Abstract 4.
   Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558–565.
   PubMed Web of Science ®Google Scholar
• Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393–4402.
   PubMed Web of Science ®Google Scholar
• VENCLEXTA (venetoclax) prescribing information. North Chicago (IL): AbbVie Inc.; 2016.
   Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–778.
   PubMed Web of Science ®Google Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35:826–833.
   PubMed Web of Science ®Google Scholar
• Albertsson-Lindblad A, Kolstad A, Laurell A, et al. Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma >65 years, the Nordic Lymphoma Group phase I + II trial NLG-MCL4. Blood. 2016;128:1814–1820.
   PubMed Web of Science ®Google Scholar
• Zaja F, Ferrero S, Stelitano C, et al. Second-line rituximab, lenalidomide, and bendamustine (R2B) in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. Haematology. 2017;102:e203–e206.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Bouabdallah K, Cartron G, et al. A multicenter phase Ib dose escalation study to evaluate the safety, feasibility and efficacy of the temsirolimus (Torisel™)-CHOP-rituximab (T-R-CHOP), temsirolimus (Torisel™)-FC-rituximab (T-R-FC) and temsirolimus (Torisel™)- DHA-rituximab (T-R-DHA) for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL): a LYSA study. Blood. 2014;124:Abstract 4426.
   PubMed Web of Science ®Google Scholar
• Hess G, Keller U, Scholz CW, et al. Safety and efficacy of temsirolimus in combination with bendamustine and rituximab in relapsed mantle cell and follicular lymphoma. Leukemia. 2015;29:1695–1701.
   PubMed Web of Science ®Google Scholar
• Furtado M, Johnson R, Kruger A, et al. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol. 2015;168:55–62.
   PubMed Web of Science ®Google Scholar
• Kouroukis CT, Fernandez LA, Crump M, et al. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma. 2011;52:394–399.
   PubMed Web of Science ®Google Scholar
• Gerecitano J, Portlock C, Hamlin P, et al. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clin Cancer Res. 2011;17:2493–2501.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Coleman M, et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010;116:2655–2664.
   PubMed Web of Science ®Google Scholar
• Lin TS, Blum KA, Fischer DB, et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol. 2010;28:418–423.
   PubMed Web of Science ®Google Scholar
• Gressin R, Daguindau N, Tempescul A, et al. First line treatment by the RiBVD regimen elicits high clinical and molecular response rates and prolonged survival in elderly MCL patients; final results of the LYSA group trial. Hematol Oncol. 2017;101:141–142. Abstract 132.
   Google Scholar
• Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944–953.
   PubMed Web of Science ®Google Scholar
• Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17:48–56.
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Hutchings M, Raty R, et al. Ibrutinib-lenalidomide-rituximab in patients with relapsed/refractory mantle cell lymphoma: first results from the Nordic Lymphoma Group MCL6 (PHILEMON) phase II trial. Blood (ASH Annual Meeting Abstracts). 2016;128:Abstract 148.
   Google Scholar
• Tam CS, Roberts AW, Anderson MA, et al. Combination ibrutinib and venetoclax for the treatment of mantle cell lymphoma: primary endpoint assessment of the phase 2 AIM study. J Clin Oncol. 2017;35:Abstract 7520.
   Web of Science ®Google Scholar
• Chong EA, Ahmadi T, Aqui NA, et al. Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas. Clin Cancer Res. 2015;21:1835–1842.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Jung SH, Johnson J, et al. Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma. 2015;56:958–964.
   PubMed Web of Science ®Google Scholar
• Zaja F, De Luca S, Vitolo U, et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica. 2012;97:416–422.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol. 2011;12:361–368.
   PubMed Web of Science ®Google Scholar
• Chiappella A, Pregno P, Zinzani PL, et al. The combination of weekly infusion of rituximab and bortezomib is effective in relapsed or refractory indolent and mantle cell lymphoma: long-term results of phase II BRIL06 study of the Fondazione Italiana Linfomi (FIL). Blood. 2015;126:Abstract 2735.
   Web of Science ®Google Scholar
• Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011;117:2442–2451.
   PubMed Web of Science ®Google Scholar
• Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. Br J Haematol. 2010;151:346–353.
   PubMed Web of Science ®Google Scholar
• Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica. 2011;96:1008–1014.
   PubMed Web of Science ®Google Scholar
• Harel S, Delarue R, Ribrag V, et al. Treatment of younger patients with mantle cell lymphoma. Semin Hematol. 2011;48:194–207.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520–531.
   PubMed Web of Science ®Google Scholar